Sun Pharma Advanced Research Company Ltd
Intimation Regarding Change in Senior Management Team of the Company
MANAGEMENT
● No Immediate Change
LOW RISK
📅 Filed on BSE: 27 Mar 2026, 06:42 PM IST · BSE ID: e8840f1b-9b1a-4ab5-8429-8222c55ae255
View Original BSE Filing (PDF)
💡
In Simple Terms
The company replaced its operations head with an internal veteran who previously worked at SPARC and Sun Pharma for three decades.
🤖 AI Summary
- Dr. Shravanti Bhowmik resigned as Vice President, Operations Management effective March 31, 2026
- Narendra Lakkad appointed Head—Corporate Development and Operations Management effective April 01, 2026
- Lakkad holds Master's degree in Pharmacology; 32-year tenure with Sun Pharma group since 1994
- Board approval via circular resolution March 27, 2026 on Nomination and Remuneration Committee recommendation
🔢 Key Numbers — exact figures from BSE filing, not rounded
Resignation effective date
March 31, 2026
New appointment effective date
April 01, 2026
Narendra Lakkad tenure in Sun Pharma group
Since 1994 (32 years)
Prior SPARC tenure (Lakkad)
2014-2018
🏢 How This Affects the Company
Operations Management leadership transition from Bhowmik to Lakkad consolidates corporate development and operations under single executive. Lakkad brings 32-year Sun Pharma group experience and prior SPARC tenure, potentially ensuring continuity in operations and business development functions.
👥 What This Means For Shareholders
✅
Action Required
No action required. Monitor Q1 FY27 business updates for operational continuity confirmation.
👤
Who Is Affected
All shareholders. No specific shareholder class affected by this management transition.
🔍
Management Signal
Board prioritized operational continuity by appointing internally experienced candidate with established Sun Pharma group relationships and prior SPARC role knowledge.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q1 FY27 operational metrics—confirm no disruption in business development or operations execution
Annual Report FY26—assess organizational structure changes and management commentary on transition impact
Next investor presentation—track corporate development pipeline and alliance management progress under Lakkad leadership
LOW RISK
Internal successor with 32-year group experience and prior SPARC tenure mitigates transition risk. No indication of operational disruption.
💡 Investor Takeaway
Routine senior management change: operations head departure balanced by appointment of 32-year Sun Pharma veteran with prior SPARC corporate development and alliance management experience. Internal successor provides operational continuity.
⚖️ Strengths & Concerns
✅ Positives
- Incoming Head brings 32-year Sun Pharma group experience and prior SPARC tenure (2014-2018) in corporate development roles
- Internal appointment with proven track record in business development, investor relations, and alliance management across group entities